Vanguard Global Advisers
EDVA

Vanguard Global Advisers’s Endovia Health Sciences, Inc. EDVA Stock Holding History

Vanguard Global Advisers’s Portfolio EDVA Stock Details EDVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38
Closed -$55 – 3718
2026
Q1 		$55 Buy
+38
New +$88 ﹤0.01% 3680

Other funds holding EDVA

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PM
Phraction Management Colchester, Connecticut $596M AUM 36.77% 1-Year Est. Return
STA
Summit Trail Advisors New York $7.95B AUM 26.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $171M AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Global Advisers's EDVA Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Endovia Health Sciences, Inc. (EDVA) in Q2 2026, closing a stake of 38 shares — an estimated $55 sold.

Vanguard Global Advisers first reported a position in EDVA in Q1 2026 and held it in 1 quarter. The position peaked at $55 in Q1 2026. 18 funds tracked by Wall St. Rank hold EDVA as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Endovia Health Sciences, Inc. position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 38 Endovia Health Sciences, Inc. shares in Q2 2026, an estimated $55.
  • Vanguard Global Advisers first reported a position in Endovia Health Sciences, Inc. in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Endovia Health Sciences, Inc. position peaked at $55 in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.